Core Insights - Castle Biosciences, Inc. is presenting new data on its TissueCypher Barrett's Esophagus test at the Digestive Disease Week® (DDW 2025) Annual Meeting, emphasizing its role in improving risk stratification and management of Barrett's esophagus patients [1][2][9] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers, Barrett's esophagus, and mental health conditions [10][11] - The TissueCypher Barrett's Esophagus test is designed to predict the future development of high-grade dysplasia and/or esophageal cancer in patients with Barrett's esophagus [9] Event Highlights - The company will showcase two posters at DDW 2025, including findings on the detection of missed neoplasia and risk stratification for Barrett's esophagus patients [3][2] - A product theater titled "The Time is Now: A Clinical Practice Model to Help Prevent Progression from Barrett's to EAC" will be hosted by an expert physician panel [1][6] Educational Collaborations - Castle is collaborating with the American Society for Gastrointestinal Endoscopy (ASGE) and other GI experts to conduct educational sessions on the use of TissueCypher [1][2]

Core Insights - Castle Biosciences, Inc. announced that its DecisionDx-Melanoma test significantly outperforms traditional methods in identifying low-risk melanoma patients who may avoid sentinel lymph node biopsy (SLNB) surgery, with a sentinel lymph node positivity rate of 2.8%, well below the NCCN's 5% threshold [1][2][3] Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that enhance patient care, with a portfolio that includes tests for skin cancers and other conditions [6][8] - The DecisionDx-Melanoma test has been ordered over 200,000 times for patients diagnosed with cutaneous melanoma, demonstrating its widespread adoption and clinical relevance [5] Study Findings - The study published in Cancer Diagnosis & Prognosis indicates that DecisionDx-Melanoma provides better risk stratification compared to the American Joint Committee on Cancer (AJCC) staging and the CP-GEP test, confirming its clinical utility [2][3] - Patients identified as low risk by CP-GEP had a sentinel lymph node positivity rate of 6.2%, while those identified by DecisionDx-Melanoma had a significantly lower rate of 2.8%, highlighting the latter's superior accuracy [3] Clinical Implications - The findings support the use of DecisionDx-Melanoma in clinical decision-making, allowing clinicians to confidently recommend forgoing SLNB for patients with low-risk results, thereby improving patient outcomes and reducing unnecessary procedures [4][5] - The test integrates tumor biology with clinical factors, providing personalized risk assessments for sentinel lymph node positivity and melanoma recurrence [5]

Core Insights - Castle Biosciences has achieved a significant milestone by surpassing 200,000 orders for its DecisionDx-Melanoma test, which aids in providing personalized insights for melanoma treatment decisions [2][7] - The DecisionDx-Melanoma test is a 31-gene expression profile test designed to improve risk-aligned management decisions for patients with stage I-III cutaneous melanoma [2][6] - The test integrates genetic information from tumor biology with traditional clinical features to stratify patient risk and predict recurrence and metastasis [4][6] Company Overview - Castle Biosciences, Inc. (Nasdaq: CSTL) focuses on improving health through innovative diagnostic tests that guide patient care [2][8] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [8] - Castle's portfolio includes tests for various conditions, including skin cancers and mental health, with ongoing research for additional tests in high clinical need areas [9] Clinical Impact - The clinical value of DecisionDx-Melanoma is supported by over 50 peer-reviewed publications and has been studied in more than 10,000 patient samples, demonstrating its association with improved patient survival [4][7] - The test provides actionable results that help clinicians make informed treatment decisions, ultimately improving patient outcomes [3][4]

FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma (CM and UM, respectively) via poster presentations at the American Association for Cancer Research® (AACR) Annual Meeting 2025, being held April 25-30 in Chicago. "At Castle Biosciences, our commitment to advancing care for melanoma patient ...

FRIENDSWOOD, Texas, April 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the first quarter ended March 31, 2025, after the close of market on Monday, May 5, 2025. Company management will host a conference call and webcast to discuss its financial results at 4:30 p.m. Eastern time on the same day. Conference Call and Webcast DetailsA live webcast of ...

Core Viewpoint - Castle Biosciences is actively promoting awareness and education regarding esophageal cancer during Esophageal Cancer Awareness Month, collaborating with various organizations to enhance prevention and early detection efforts [1][2][3]. Company Initiatives - Castle Biosciences is collaborating with the Esophageal Cancer Action Network (ECAN), the American Foregut Society (AFS), and The Gut Doctor Podcast to support educational programs and initiatives throughout April [1][3]. - The company is utilizing a digital media campaign and awareness kits to disseminate information about esophageal cancer, emphasizing its preventability and the importance of early detection [3][4]. - Castle's TissueCypher® test is designed to assess the risk of Barrett's esophagus patients progressing to esophageal cancer, which is crucial for timely intervention [2][11]. Industry Context - Esophageal cancer has a low five-year survival rate of approximately 20%, often diagnosed at advanced stages, highlighting the need for increased awareness and early detection [2][4]. - The incidence of esophageal cancer is rising, particularly among young individuals, making awareness and education critical in combating this disease [4][8]. - The collaboration with advocacy groups aims to increase federal funding for esophageal cancer research, which has seen an increase of over $20 million in the past four years [8].

Company Overview - Castle Biosciences, Inc. is a diagnostics company focused on improving health through innovative tests that guide patient care [4] - The company has a portfolio that includes tests for skin cancers, Barrett's esophagus, mental health conditions, and uveal melanoma, with ongoing research for additional tests [5] Awards and Recognition - Castle Biosciences has received the Top Workplaces USA Award for the fourth consecutive year, ranking 30th among 358 participating U.S. companies with 500-999 employees [1] - The award is based on employee feedback collected through a third-party engagement survey, with Castle achieving a participation rate of 95% and an engagement score of 85%, both exceeding industry benchmarks [2] Leadership and Culture - The CEO of Castle Biosciences emphasized the importance of a people-first culture that values and empowers employees, which is reflected in the company's recognition [2] - Energage, the organization behind the award, highlighted that companies earning this recognition are seen as having a strong employee voice and culture, which is crucial in today's market [3]

Core Insights - Castle Biosciences' DecisionDx-Melanoma test effectively identifies patients with less than 5% risk of sentinel lymph node (SLN) positivity, allowing them to safely forgo sentinel lymph node biopsy (SLNB) [1][2][3] - The DECIDE study demonstrated that all patients with a low-risk DecisionDx-Melanoma test result (Class 1A) were recurrence-free, indicating the test's reliability in predicting long-term outcomes [1][2][3] - The test significantly influences clinical decision-making, with 85% of SLNB decisions being affected by its results, thereby reducing unnecessary procedures and associated costs [2][3] Company Overview - Castle Biosciences, Inc. (Nasdaq: CSTL) focuses on innovative diagnostic tests that enhance patient care, with a portfolio that includes tests for skin cancers and other conditions [5][6] - The DecisionDx-Melanoma test has been ordered approximately 191,800 times for patients diagnosed with cutaneous melanoma, reflecting its widespread adoption and clinical relevance [4][6] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [5]

Core Insights - Castle Biosciences, Inc. will present data on the DecisionDx-Melanoma test at the 11th World Congress of Melanoma and the 21st European Association of Dermato-Oncology Congress, highlighting its role in risk stratification for patients with stage IIB-IIC cutaneous melanoma [1][2] Group 1: DecisionDx-Melanoma Test - The DecisionDx-Melanoma test provides significant biological insights that enhance traditional staging, allowing clinicians to tailor surveillance and treatment plans based on individual risk of metastasis [2] - The test has been shown to improve melanoma outcomes by identifying patients who may benefit from intensified monitoring and adjuvant therapy [2][6] - DecisionDx-Melanoma has been ordered over 191,000 times for patients diagnosed with cutaneous melanoma, demonstrating its clinical value supported by more than 50 peer-reviewed studies [6][7] Group 2: Research Findings - A study presented at EADO indicates that DecisionDx-Melanoma effectively stratifies melanoma-specific survival and overall survival in patients with stage IIB-IIC cutaneous melanoma, with a p-value of less than 0.001 [5] - Another study shows that the test can identify patients with localized cutaneous melanoma at high risk of CNS metastasis within the first three years post-diagnosis, with a hazard ratio of 9.21 [5] - The DecisionDx-Melanoma Class 2B result is a significant predictor of CNS metastasis, emphasizing the need for more frequent imaging surveillance for high-risk patients [5]

Core Insights - Castle Biosciences presented new data on its risk-stratification tests, DecisionDx-SCC and DecisionDx-Melanoma, at the NCCN 2025 Annual Conference, highlighting their significant prognostic capabilities in enhancing risk stratification for skin cancer patients [1][2] Group 1: DecisionDx-SCC - A study involving 1,412 high-risk squamous cell carcinoma (SCC) patients demonstrated that integrating DecisionDx-SCC with Brigham & Women's Hospital (BWH) staging significantly improves metastatic risk prediction, with a p-value of less than 0.001 [4] - The combination of DecisionDx-SCC with BWH staging resulted in nearly a two-fold decrease in metastatic risk for Class 1 (low risk) patients and over a five-fold increase in risk for Class 2B (highest risk) patients in lower-stage NCCN High-Risk categories [4][9] - DecisionDx-SCC is a 40-gene expression profile test that categorizes patients into risk classes to inform management decisions, showing independent predictive value when integrated with existing prognostic methods [9] Group 2: DecisionDx-Melanoma - New validation data for DecisionDx-Melanoma indicated its effectiveness in predicting mortality in a real-world cohort of nearly 7,000 early-stage cutaneous melanoma patients, identifying individuals at higher risk than traditional AJCC8 staging [5][7] - The test demonstrated significant independent risk-stratification capabilities, aiding in the identification of patients who may benefit from enhanced surveillance and management strategies [7][10] - DecisionDx-Melanoma has been ordered over 191,000 times for patients diagnosed with cutaneous melanoma, supporting its clinical value through extensive peer-reviewed studies [10] Group 3: Company Overview - Castle Biosciences is a diagnostics company focused on innovative tests that guide patient care, with a portfolio that includes tests for skin cancers and other conditions [11][12] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [11]